Antipsychotic Drugs May Worsen Metabolic Control in Type 2 Diabetes Mellitus

2004 ◽  
Vol 65 (5) ◽  
pp. 674-678 ◽  
Author(s):  
José A. Spoelstra ◽  
Ronald P. Stolk ◽  
Dan Cohen ◽  
Olav H. Klungel ◽  
Joëlle A. Erkens ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Metabolic Control ◽  
Antipsychotic Drugs

scholarly journals Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus

2014 ◽  
Vol 58 (4) ◽  
pp. 369-376 ◽  
Author(s):  
Joelma Ines Tagliapietra Barros ◽  
Francisco Vagnaldo Fechine ◽  
Renan Magalhães Montenegro Júnior ◽  
Otoni Cardoso do Vale ◽  
Virgínia Oliveira Fernandes ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Evoked Potentials ◽  
Metabolic Control ◽  
Somatosensory Evoked Potentials ◽  
Before And After ◽  
Effect Of Treatment ◽  
Established Role

Objective: To evaluate the effect of sitagliptin on somatosensory-evoked potentials (SEPs) and metabolic control in patients with type 2 diabetes mellitus without clinical diabetic neuropathy. Materials and methods: Interventional, prospective, and open study. Patients with less than six months from the diagnosis were included. Examinations of SEPs and laboratory tests at fasting and after food stimulation were performed before and after three months of treatment with sitagliptin (100 mg/day). Results: There was a reduction in the mean levels of HbA1c (P < 0.0001), fasting glucose (P = 0.001), total cholesterol (P = 0.019), and ALT (P = 0.022). An increase in active GLP-1 was found at the end of the study (P = 0.0025). Several SEPs showed statistically significant differences when analyzed before and after treatment with sitagliptin. Conclusion: The results give a glimpse of the possible use of sitagliptin in the treatment of some neurodegenerative conditions of the peripheral nervous system, in addition to its already established role in glycemic control.

scholarly journals Type 2 diabetes mellitus metabolic control correlates with the phenotype of human monocytes and monocyte-derived macrophages

2020 ◽  
Vol 34 (11) ◽  
pp. 107708
Author(s):  
M.A. Valtierra-Alvarado ◽  
J.E. Castañeda Delgado ◽  
S.I. Ramírez-Talavera ◽  
G. Lugo-Villarino ◽  
F. Dueñas-Arteaga ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Metabolic Control ◽  
Human Monocytes

scholarly journals The effects of aerobic, resistance, and combined exercise on metabolic control, inflammatory markers, adipocytokines, and muscle insulin signaling in patients with type 2 diabetes mellitus

Metabolism ◽  
2011 ◽  
Vol 60 (9) ◽  
pp. 1244-1252 ◽  
Author(s):  
Maria Luiza Mendonça Pereira Jorge ◽  
Vanessa Neves de Oliveira ◽  
Nathalia Maria Resende ◽  
Lara Ferreira Paraiso ◽  
Antonio Calixto ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Metabolic Control ◽  
Insulin Signaling ◽  
Inflammatory Markers ◽  
Combined Exercise

scholarly journals Application of Liquid Chromatography with Fluorimetric Detection for the Determination of Urinary Pentosidine in Type 2 Diabetes Mellitus Patients: Effect of Telmisartan Administration on Podocyturia and Relationship with Metabolic Control

2018 ◽  
Vol 62 (2) ◽  
Author(s):  
Carlos Kornhauser ◽  
Gloria Barbosa-Sabanero ◽  
Noemí Gutierrez-Romero ◽  
Myrna Sabanero ◽  
Elva L. Perez-Luque ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Diabetic Nephropathy ◽  
Metabolic Control ◽  
Fluorimetric Detection ◽  
Beneficial Effects ◽  
Short Period ◽  
The Face

The beneficial effects of a short period of Telmisartan administration were successfully assessed trough pentosidine urinary levels (uPen) and urinary podocyte excretion (UPE), in type 2 diabetes mellitus (DM2) patients. Patients with podocyturia received Telmisartan treatment (80 mg/day) for two months.  uPen were quantified pre and post treatment using HPLC with fluorimetric detection and in-lab synthesized standard. Immunofluorescence method for podocalyxin was used to evaluate urinary excretion of podocytes. uPen and UPE significantly decrease after treatment (p&lt;0.01255 and p&lt;0.005 respectively), as well as serum total cholesterol and LDL levels (p&lt;0.001). These results suggest that podocyte protection by Telmisartan even in the face of deficient metabolic control could be an important matter in the prevention and progression of diabetic nephropathy. This study also strengthens evidence of the promising role of pentosidine as prognostic and diagnostic markers in diabetic nephropathy

Sign in / Sign up

Export Citation Format

Share Document